Head of the FDA, Scott Gottlieb has suggested some ways in which pharma giants could rethink their business models, to help unproductive drugmakers.
Genomic data can have a significant effect on other areas of society. Insurance premiums, familial impact, identification. As we enter the genomic era, policy will need to reflect these new considerations.
The FDA has approved Seattle Genetics’ Hodgkin’s lymphoma treatment, which is the first to be approved to treat the disease in over 40 years.
Experts have revealed that cut-price copies of an expensive Roche biotech drug for blood cancer have taken 80% of the British market since launching last year, saving the healthcare system £80 million a year.
The World Health Organisation (WHO) has put scientists and health workers around the globe on alert for a new and potentially deadly pathogen – Disease X.
The HHS civil rights division refocuses on the rights of health care providers who have moral objections to treatments such as abortion or sterilization, alarming critics.
FDA Commissioner Scott Gottlieb said he will do everything “within my lane” to combat high drug prices and that he sees drug companies “gaming the system to try to block competition” in a multitude of ways in the marketplace.
At a biohacking conference this week, a biotech CEO dropped his pants and injected himself in the thigh with an experimental herpes treatment created by his company, leaving other biohackers worried.